PURPOSE: A rapid immune response is required to prevent death from Anthrax, caused by Bacillus anthracis. METHOD: We formulated a vaccine carrier comprised of acetalated dextran microparticles encapsulating recombinant protective antigen (rPA) and resiquimod (a toll-like receptor 7/8 agonist). RESULTS: We were able to protect against triplicate lethal challenge by vaccinating twice (Days 0, 7) and then aggressively challenging on Days 14, 21, 28. A significantly higher level of antibodies was generated by day 14 with the encapsulated group compared to the conventional rPA and alum group. Antibodies produced by the co-encapsulated group were only weakly-neutralizing in toxin neutralization; however, survival was not dependent on toxin neutralization, as all vaccine formulations survived all challenges except control groups. Post-mortem culture swabs taken from the hearts of vaccinated groups that did not produce significant neutralizing titers failed to grow B. anthracis. CONCLUSIONS: Results indicate that protective antibodies are not required for rapid protection; indeed, cytokine results indicate that T cell protection may play a role in protection from anthrax. We report the first instance of use of a particulate carrier to generate a rapid protective immunity against anthrax.
PURPOSE: A rapid immune response is required to prevent death from Anthrax, caused by Bacillus anthracis. METHOD: We formulated a vaccine carrier comprised of acetalated dextran microparticles encapsulating recombinant protective antigen (rPA) and resiquimod (a toll-like receptor 7/8 agonist). RESULTS: We were able to protect against triplicate lethal challenge by vaccinating twice (Days 0, 7) and then aggressively challenging on Days 14, 21, 28. A significantly higher level of antibodies was generated by day 14 with the encapsulated group compared to the conventional rPA and alum group. Antibodies produced by the co-encapsulated group were only weakly-neutralizing in toxin neutralization; however, survival was not dependent on toxin neutralization, as all vaccine formulations survived all challenges except control groups. Post-mortem culture swabs taken from the hearts of vaccinated groups that did not produce significant neutralizing titers failed to grow B. anthracis. CONCLUSIONS: Results indicate that protective antibodies are not required for rapid protection; indeed, cytokine results indicate that T cell protection may play a role in protection from anthrax. We report the first instance of use of a particulate carrier to generate a rapid protective immunity against anthrax.
Authors: L Lu; S J Peter; M D Lyman; H L Lai; S M Leite; J A Tamada; S Uyama; J P Vacanti; R Langer; A G Mikos Journal: Biomaterials Date: 2000-09 Impact factor: 12.479
Authors: E D Williamson; I Hodgson; N J Walker; A W Topping; M G Duchars; J M Mott; J Estep; C Lebutt; H C Flick-Smith; H E Jones; H Li; C P Quinn Journal: Infect Immun Date: 2005-09 Impact factor: 3.441
Authors: Dianna Rynkiewicz; Melinda Rathkopf; Iain Sim; A Thomas Waytes; Robert J Hopkins; Lallan Giri; Deborah DeMuria; Janet Ransom; James Quinn; Gary S Nabors; Carl J Nielsen Journal: Vaccine Date: 2011-05-30 Impact factor: 3.641
Authors: Bojana Stojkovic; Eric M Torres; Angela M Prouty; Hetal K Patel; Lefan Zhuang; Theresa M Koehler; Jimmy D Ballard; Steven R Blanke Journal: Appl Environ Microbiol Date: 2008-06-13 Impact factor: 4.792
Authors: Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Michael A Collier; Rebekah Watkins-Schulz; Ning Cheng; Clément N David; Charles E McGee; Gregory D Sempowski; Ivo Shterev; Karen McKinnon; Eric M Bachelder; Kristy M Ainslie; Jenny P-Y Ting Journal: J Control Release Date: 2017-11-21 Impact factor: 9.776
Authors: Rebekah Watkins-Schulz; Pamela Tiet; Matthew D Gallovic; Robert D Junkins; Cole Batty; Eric M Bachelder; Kristy M Ainslie; Jenny P Y Ting Journal: Biomaterials Date: 2019-03-14 Impact factor: 12.479
Authors: Michael A Collier; Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Monica M Johnson; Andrew N Macintyre; Gregory D Sempowski; Eric M Bachelder; Jenny P-Y Ting; Kristy M Ainslie Journal: Mol Pharm Date: 2018-10-15 Impact factor: 4.939
Authors: Kathryn M Moore; Cole J Batty; Rebeca T Stiepel; Christopher J Genito; Eric M Bachelder; Kristy M Ainslie Journal: ACS Appl Mater Interfaces Date: 2020-08-24 Impact factor: 9.229
Authors: Melissa A Kachura; Colin Hickle; Sariah A Kell; Atul Sathe; Carlo Calacsan; Radwan Kiwan; Brian Hall; Robert Milley; Gary Ott; Robert L Coffman; Holger Kanzler; John D Campbell Journal: J Immunol Date: 2015-11-25 Impact factor: 5.422